Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16072689 | 0.89 | ELANE (0.45) | ALDH1A1HSD17B10ELANEMTNR1AMTNR1B | |
| SCHEMBL16111382 | 0.88 | HSD17B10 (0.54) | ALDH1A1HSD17B10MTNR1AMTNR1BBAZ2B | |
| SCHEMBL18200168 | 0.81 | MTNR1A (0.48) | ALDH1A1ELANEMTNR1AMTNR1BHTR2A | |
| SCHEMBL16045985 | 0.80 | HSD17B10 (0.57) | ALDH1A1HSD17B10MTNR1AMTNR1BHTR2A | |
| SCHEMBL13337963 | 0.79 | ELANE (0.51) | ALDH1A1ELANEMTNR1AMTNR1B | |
| SCHEMBL16072688 | 0.77 | ALDH1A1 (0.51) | ALDH1A1ELANE | |
| SCHEMBL19484783 | 0.77 | ELANE (0.46) | ALDH1A1ELANEMTNR1AMTNR1B | |
| SCHEMBL19490345 | 0.77 | ELANE (0.55) | ALDH1A1ELANE | |
| SCHEMBL487944 | 0.76 | HSD17B10 (0.62) | HSD17B10MTNR1AMTNR1BHTR2A | |
| SCHEMBL23258511 | 0.76 | ELANE (0.50) | ALDH1A1HSD17B10ELANEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | CLN6, AREG, HASPIN | ALDH1A1 751/4885HSD17B10 1388/4885ELANE 145/4885 |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | CLN6, AREG, HASPIN | ALDH1A1 751/4885HSD17B10 1388/4885ELANE 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.